ImmunityBio (IBRX) FCF Margin (2014 - 2026)
ImmunityBio (IBRX) posted quarterly FCF Margin of 172.94% for Q1 2026, up 34716.0% year-over-year from N/an in Q1 2025, and up 6.92% quarter-over-quarter from 185.8% in Q4 2025.
ImmunityBio (IBRX) FCF Margin (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported FCF Margin for 13 consecutive years, with 172.94% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 34716.0% year-over-year to 172.94%; the TTM figure through Mar 2026 stood at 210.53% (up 97455.0% YoY), while the FY2025 annual figure was 270.33%, up 239053.0% from the prior year.
- FCF Margin climbed to 172.94% in Q1 2026 per IBRX's latest filing, from 185.8% in the prior quarter.
- Across five years, FCF Margin topped out at 172.94% in Q1 2026 and bottomed at 534492.86% in Q1 2022.
- Historically, FCF Margin has averaged 107467.1% across 5 years, with a median of 28706.39% in 2023.
- Annual changes were most pronounced in 2022 — FCF Margin slumped 48792020 bps — and 2023, when it surged 50578647 bps.
- ImmunityBio's FCF Margin stood at 150216.44% in 2022, then surged by 51 bps to 73816.55% in 2023, then jumped by 99 bps to 1078.85% in 2024, then surged by 83 bps to 185.8% in 2025, then rose by 7 bps to 172.94% in 2026.
- Business Quant data shows IBRX's FCF Margin at 172.94% in Q1 2026, 185.8% in Q4 2025, and 209.66% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | -136.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -136.64% |
| Mar 31, 2026 | -172.94% |
| Dec 31, 2025 | -185.80% |
| Sep 30, 2025 | -209.66% |
| Jun 30, 2025 | -310.30% |
| Mar 31, 2025 | -520.10% |
| Dec 31, 2024 | -1,078.85% |
| Sep 30, 2024 | -1,646.66% |
| Jun 30, 2024 | -9,749.86% |
| Mar 31, 2024 | -270,607.50% |
| Dec 31, 2023 | -73,816.55% |
| Sep 30, 2023 | -99,208.54% |
| Jun 30, 2023 | -189,497.56% |
| Mar 31, 2023 | -28,706.39% |
| Dec 31, 2022 | -150,216.44% |
| Sep 30, 2022 | -81,809.32% |
| Jun 30, 2022 | -384,711.43% |
| Mar 31, 2022 | -534,492.86% |
| Dec 31, 2021 | -18,146.67% |
| Sep 30, 2021 | -111,153.03% |